The light of the original national research shines 2020 ESMO - Heng Rui with 32 studies to play China's strongest sound.

In the published agenda for the 2020 ESMO conference, Hengrui Pharmaceuticals, the leader of China's national pharmaceutical companies, selected 32 studies, including 2 LBA, 2 mini oral, and 28 e-posters; Karelli pearl monotherapy, covering the treatment areas include: thyroid cancer, lung cancer, hepatocellular carcinoma, bile tube cancer, esophageal cancer, stomach cancer, breast cancer, nasopharyngeal cancer, lymphoma, cartilage sarcoma, among which the field of blood tumors is the first time that research has been selected, in the ESMO stage played China's strongest voice.
let's take a quick look at this selected study.
Thyroid cancer was selected for a multi-center randomized Phase III. trial of Apatini's treatment of local progression or metastatic radioactive iodine incurable differentiated thyroid cancer conducted by Professor Lin Yansong of Concord Hospital in Beijing.
previous studies have tentatively confirmed that apatinib has shown clinical activity in the treatment of patients with radioactive iodine incurable differentiated thyroid cancer (RAIR-DTC).
this study aims to further validate and analyze the efficacy of apatinib in the treatment of local progression or metastasis OFR-DTC (this study has been accepted as mini oral).
Lung Cancer was selected for another LBA study, a multi-center, randomized, double-blind Phase III clinical study of patients with advanced cell growth factor mutant (EGFRm) non-small cell lung cancer (NSCLC) in the first-line treatment of advanced gefeitinib by a team of professors of stress at Sun Yat-sen University's Center for Cancer Prevention and Control.
has been clinically found to improve the therapeutic effect of EGFR-TKI on EGFRm NSCLC by blocking the path of vascular endothort growth factor(VEGFR) mediated.
the study was designed to assess the outcome of the treatment of apatinib or placebo combined gyfroteni in patients with EGFRm NSCLC (this study has been accepted as profered oral).
Lymphoma Blood Tumor field is the first time Hengrui has been selected for research.
The study of Apatini's joint Karelli pearl monoanti (SHR-1210) for the treatment of recurring/refractic exotremic T-cell lymphoma (R/R PTCL), initiated by Professor Song Yuqin's team at Peking University Cancer Hospital, was selected for the mini oral session of the conference, and the single-arm trial of the II.phase single-center was designed to explore the feasibility of Apatini's combined Karelli pearl monotherapy R/R PTCL.
In addition, a randomized controlled non-poor performance study conducted by Professor Su Liping of Shanxi Cancer Hospital to improve the reduction of neutral granulocytes due to chemotherapy in patients with lymphoma was selected for this meeting e-poster to assess the effectiveness and safety of thiopfeigsting in such patients.
nasopharyngeal cancer Karelli pearl monoantigen as an excellent representative of domestic PD-1 antibodies has shown good anti-tumor activity.
The other study selected for mini oral was also carried out by a team of professors at Sun Yat-sen University's Center for Cancer Prevention and Control, carried out by The KarelliJudan anti-treatment of patients with relapsed/metastatic nasopharyngeal cancer (NPC) who had progressed after 2 lines and above chemotherapy, single-arm, open label, multi-center, Phase II study: CAPTAIN.
breast cancer in the field of breast cancer, Henri this time a total of 6 studies selected e-poster, involving products including apatini and pyridoxine.
Apatini-related studies included" multi-center, randomized, phase II. phase, open-label studies of the new complementary treatment of triple-negative and HER2-positive breast cancers in Apatini combined with platinum, and "Apatinist reverses the mechanisms of tantafine resistance in breast cancer."
has been shown to have good efficacy and safety in the treatment of HER2-positive advanced breast cancer.
, however, will the double HER2 blocker of pyridoxine combined with clopidozhu monoantigen have a better effect in the new complementary treatment of early breast cancer? Based on this, a single-arm, multi-center, and Phase II study on the new assisted treatment of HER2-positive breast cancer patients in pyridoxine, dossythal, and capratin is designed to explore this issue.
In addition, studies on the use of pyridoxine for breast cancer treatment include the Phase II study of the new assisted treatment of HER2-positive early or local advanced breast cancer with pyridoxine and quercetinyl monotherapy, the single-arm, multi-center, Phase II study of hertinist treatment of 2HER-positive breast cancer in patients with untreated brain metastasis.
esophageal tumors The research in the field of gastrointestinal tumors presented at the ESMO conference, including esophageal, stomach, and colorectal cancers, involved products such as carellijudone and apatinist.
In the case of carelli's monoantigen, the studies selected include the study of Karelli's monotherapy for the treatment of advanced esophageal squamous cell carcinoma (ESCC) as a monotherapy, and the study of the partial late stage or metastatic ESCC for the treatment of carelli's pearl monotherapy or apatinib alone.
the feasibility of drug combination therapy strategies by analyzing data from patients with local late stage or metastasis ESCC in two studies.
addition to this, Karelli's mono-anti-combined apatini to treat advanced stomach and colorectal cancer: a one-arm exploratory clinical study was also selected for this meeting.
in the case of apatini, one of them was a Phase II clinical study on the treatment of siewert II. type III. HER2-negative gastroesophageal junction adenocarcinoma in combination with new assisted synchronous chemotherapy.
the study was designed to assess the effectiveness and safety of the new assisted chemotherapy combination with apatini.
In addition, the studies selected for the conference included: "Forward-looking multi-center randomized controlled study of apatinib combined FLT program periter chemotherapy and surgical treatment III. stage gastric cancer," "Apatini combined POF (yew alcohol and FOLFOX) treatment of patients with advanced gastric cancer (TGCNA) Phase I study," "Apatini combined synchronous chemotherapy treatment of non-extincisive esophageal cancer patients efficacy and safety." Changes in the tumor immuno-micro-environment of different new aids for the treatment of esophageal squamous cancer," "forward-looking study of the new auxiliary treatment of local advanced esophageal squamous cell carcinoma with a combination of apatinib chemotherapy," "One arm, open label, forward-looking, multi-center study of the second-line treatment of advanced gastric cancer by apatinib combined with dositan: forward-looking clinical studies (data updates) " and so on.
In addition to the areas described above, Heng Rui's research at this ESMO conference also covers a number of recent studies in the fields of liver cancer, cartilage sarcoma, ovarian/fallopian tube/primary peritary cancer and advanced cervical cancer.
Hengrui Pharmaceuticals this "light", once again to show the world the rise of China's national pharmaceutical enterprises.
of more than 10 research results will certainly promote the accelerated development of China's oncology field, benefiting more Chinese people can afford, use high-quality "national medicine."
.